<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071095</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 13-0482</org_study_id>
    <secondary_id>Campbell Foundation</secondary_id>
    <secondary_id>1R21AI110736-01</secondary_id>
    <nct_id>NCT02071095</nct_id>
  </id_info>
  <brief_title>Enhancement by Poly-ICLC During HIV-1 Infection</brief_title>
  <acronym>Poly-ICLC</acronym>
  <official_title>Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nina Bhardwaj</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Campbell Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncovir, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves researching new approaches to treating HIV infection. Currently, HIV
      infection is treated with combinations of drugs called antiretrovirals. These drugs protect
      cells from infection by interfering with the viruses' ability to make copies of itself by
      infecting new target cells. Though these drugs are very effective, they cannot cure HIV
      infection and must be taken each and every day at prescribed doses to maintain their
      beneficial effect. This research study is investigating a new approach that involves an
      addition to existing medications.

      The study is investigating a medication called Poly-ICLC (Hiltonol®, Oncovir), which is an
      adjuvant. Adjuvants are medications that are designed to boost your body's immune responses
      resulting from a vaccine. The investigators want to test whether Poly-ICLC is an adjuvant
      that is effective in HIV-infected patients. A vaccine is not given in this study, but just
      investigating the adjuvant, Poly-ICLC, to determine whether it may be safe and useful in
      future vaccines that could be used to treat HIV, called therapeutic vaccines. One goal of
      future therapeutic vaccines is to reduce the virus that remains persistently inside of cells
      in a dormant or resting state despite treatment with HIV medications. This persistent pool is
      termed the &quot;latent virus pool&quot; or &quot;viral reservoir&quot;. One tactic to reduce this viral
      reservoir is to first stimulate HIV to start replicating in order to force it out of hiding.
      Once viral replication occurs, the infected cells may then be recognized and killed by cells
      of the immune system. Therefore, we also want to see what effect Poly-ICLC has on the virus
      that lives inside of cells. Specifically, the investigators want to look at whether Poly-ICLC
      increases the level of virus inside your cells while also improving your immune system's
      responses.

      The investigators are doing this research in hope to find new ways to treat HIV infection
      that may reduce exposure to medications that are called antiretrovirals. Antiretrovirals are
      medications used to treat HIV infection. They are very effective but have side effects and
      have to be taken each and every day and cannot cure HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective combination antiretroviral therapy (cART) has dramatically altered the morbidity
      and mortality associated with human immunodeficiency virus (HIV-1) infection. Nevertheless,
      the current treatment paradigm of lifelong antiviral therapy with near perfect patient
      adherence to avoid the emergence of drug resistant HIV remains less than ideal and this
      therapeutic approach has clear limitations.

      In addition to long term toxicities associated with currently preferred therapies,
      combination therapy for HIV-1 infection cannot address the issue of viral persistence. HIV-1
      persists in both blood and tissue despite long-term suppression with antiretroviral agents
      (ARVs). Eradication strategies for HIV-1 are likely to require a multi-faceted approach to
      reduce the latent reservoir, with key components focusing upon both the disruption of viral
      latency and the enhancement of cytotoxic T lymphocyte (CTL) function to promote killing of
      infected cells. In order to successfully achieve these objectives, agents that safely
      stimulate replication of the latent reservoir AND explore approaches to enhance HIV-specific
      adaptive immunity to augment CTL function must be investigated. The investigators propose
      that this may be accomplished with a single therapeutic modality that is devised
      appropriately. Certain adjuvants may possess immunostimulatory properties that trigger
      transient activation of viral transcription while simultaneously enhancing HIV-specific CTL
      function and, thus, may play an important role in such a vaccine.

      Here, the investigators propose a proof of concept clinical trial to determine the ability of
      Poly-ICLC (Hiltonol®, Oncovir), to safely activate the latent viral reservoir and enhance
      innate immunity when administered to HIV-infected individuals. This randomized,
      double-blinded, placebo-controlled study will administer two doses of Poly-ICLC to
      HIV-infected individuals whom are virologically suppressed on combination anti-retroviral
      therapy (cART). The investigators hypothesize that Poly-ICLC will be safe and well-tolerated
      and will transiently disrupt viral latency while enhancing innate immune responses. Should
      this be the case, then Poly-ICLC would be an ideal modality to combine with a therapeutic HIV
      vaccine to reduce the number of latently infected CD4+ T cells in treated HIV-1 infected
      individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 26, 2016</completion_date>
  <primary_completion_date type="Actual">July 26, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Participants With Adverse Events</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Safety measured by number of participants with adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Interferon-gamma-inducible Protein-10 (IP-10) Level</measure>
    <time_frame>Day 2 and Day 4</time_frame>
    <description>One of the biomarkers of cellular immune activation and exhaustion quantified by flow cytometry. Normal range is 7.8-500 pg/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 CD38 (Mean of Fluorescence)</measure>
    <time_frame>Day 8</time_frame>
    <description>the CD38-activation marker on CD8 T-cells (CD8/CD38).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK Cell Number</measure>
    <time_frame>at 48 weeks</time_frame>
    <description>Natural killer cells or NK cells are part of the innate immune defense against infection and cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in CD4+ Tcell-associated HIV-1 RNA as Compared to Baseline</measure>
    <time_frame>Baseline, Day 2, Day 4, Day 8, Day 28</time_frame>
    <description>CD4+ Tcell-associated HIV-1 RNA to determine whether Poly-ICLC disrupts viral latency in HIV-1-infected individuals on anti-retroviral therapy.Viral transcription assessed by monitoring cell associated HIV-1 RNA. Percent change compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV-1 Infected Adults With Chronic HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: Poly-ICLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A (N=15): Patients will receive an injection of 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir) subcutaneously on day 1 and day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm B: (N=5): Patients will receive an injection of normal saline subcutaneously on day 1 and day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A: Poly-ICLC</intervention_name>
    <description>Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.</description>
    <arm_group_label>Arm A: Poly-ICLC</arm_group_label>
    <other_name>Poly-ICLC (Hiltonol®, Oncovir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm B: Normal Saline</intervention_name>
    <description>Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.</description>
    <arm_group_label>Arm B: Normal Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection documented by previous HIV-1 serology or rapid test, or documented
             plasma HIV-1 RNA of &gt;2000 copies/ml

          -  On stable cART regimen in accordance with the DHHS &quot;Guidelines for the Use of
             Antiretroviral Agents in HIV-1-Infected Adults and Adolescents&quot; with documented
             virologic suppression (VL&lt;50 copies/ml) for ≥ 48 weeks.

          -  Baseline cell associated HIV-1 RNA is detectable (≥10copies/µg RNA)

          -  Laboratory values obtained within 30 days prior to study entry.

               -  VL &lt; 50 copies/ml

               -  CD4+ T cell count &gt; 500 cells/mm3

               -  Absolute neutrophil count (ANC) ≥500/mm3

               -  Hemoglobin ≥9.0 g/dL if female; 10 g/dL if male

               -  Platelet count ≥75,000/mm3

               -  AST (SGOT), ALT (SGPT) ≤3.5 × ULN

               -  Alkaline phosphatase&lt; 2.5 ULN

               -  Total bilirubin ≤2.5 x ULN

               -  Lipase ≤2.5 x ULN

               -  Calculated creatinine clearance ≥70 mL/min as estimated by the Cockcroft-Gault
                  equation:

          -  For men(140-age in yrs)x(body wt in kg)÷(serum creatinine in mg/dLx72)=CrCl (mL/min)*

             *For women, multiply the result by 0.85 = CrCl (mL/min)

          -  NOTE: A program to assist in calculations is available on the DMC web site at:
             http://www.fstrf.org/ACTG/ccc.html

          -  For women of reproductive potential, negative serum or urine pregnancy test

          -  Female candidates of reproductive potential is defined as girls who have reached
             menarche or women who have not been post-menopausal for at least 24 consecutive months
             (i.e., who have had menses within the preceding 24 months) or have not undergone
             surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, or bilateral
             tubal ligation).

          -  Contraception requirements

          -  Female candidates of reproductive potential, who are participating in sexual activity
             that could lead to pregnancy, must agree that they will use at least two reliable
             barrier methods of contraception while receiving the protocol-specified treatments and
             for at least 24 weeks after completing stage I of the study.

          -  Men and women aged 18-55 years.

          -  Ability and willingness of subject to give written informed consent.

          -  Adequate venous access for phlebotomy

        Exclusion Criteria:

          -  Previous immune based therapy

          -  History of vascular disease including h/o coronary artery disease, angina/MI, TIA/CVA,
             peripheral vascular disease/claudication

          -  Strong family history of cardiovascular disease

          -  Hyperlipidemia requiring medication

          -  Diabetes

          -  History of Tobacco use (≥10 pack years)

          -  HIV-related nephropathy

          -  History of vascular disease including history of coronary artery disease, angina/MI,
             TIA/CVA, peripheral vascular disease/claudication, poorly controlled hypertension

          -  Pregnancy or currently breast-feeding

          -  Desire to become pregnant during the course of study

          -  Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), systemic
             cytotoxic chemotherapy, or investigational therapy within 30 days prior to study
             entry.

          -  Known allergy/sensitivity to study drugs or their formulations.

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.

          -  History of autoimmunity

          -  Chronic Hepatitis B (HepBSAg+) or C (HCV RNA positive)

          -  Current imprisonment or involuntary incarceration in a medical facility for
             psychiatric or physical (e.g., infectious disease) illness.

          -  Participation in any other clinical trial within 30 days prior to screening.

          -  Receipt of routine vaccination(s) within 7 days of study entry, or anticipated receipt
             of routine vaccination(s) during the first 4 weeks of the study. If routine
             vaccinations are to be administered following the first 4 weeks of the study, they
             cannot be administered within 7 days prior to weeks 16 and 48 follow up visits.

          -  Multi-drug resistant (MDR) HIV-1 precluding standard 3-drug therapy

          -  Any other clinical conditions or prior therapy that, in the opinion of the
             investigator, would make the subject unsuitable for the study or unable to comply with
             the requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Bhardwaj, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Icahn School of Medicine at Mt. Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Markowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aaron Diamond AIDS Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.</citation>
    <PMID>22837004</PMID>
  </reference>
  <reference>
    <citation>Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012 Mar 23;36(3):491-501. doi: 10.1016/j.immuni.2012.01.014. Epub 2012 Mar 8.</citation>
    <PMID>22406268</PMID>
  </reference>
  <reference>
    <citation>Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, Bhat S, Zhang H, Margolick JB, Quinn TC, Margolis DM, Siliciano JD, Siliciano RF. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol. 2011 Jun;85(12):6060-4. doi: 10.1128/JVI.02033-10. Epub 2011 Apr 6.</citation>
    <PMID>21471244</PMID>
  </reference>
  <reference>
    <citation>Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today. 2013 Jun;18(11-12):541-51. doi: 10.1016/j.drudis.2012.12.008. Epub 2012 Dec 25. Review.</citation>
    <PMID>23270785</PMID>
  </reference>
  <reference>
    <citation>Elliot, J., et al. The Safety and Effect of Multiple Doses of Vorinostat on HIV Transcription in HIV+ Patients Receiving cART. in Conference on Retroviruses and Opportunistic Infections (CROI) (2013).</citation>
  </reference>
  <reference>
    <citation>Almeida M, Cordero M, Almeida J, Orfao A. Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS. 2005 Feb 18;19(3):261-71.</citation>
    <PMID>15718836</PMID>
  </reference>
  <reference>
    <citation>Almeida M, Cordero M, Almeida J, Orfao A. Persistent abnormalities in peripheral blood dendritic cells and monocytes from HIV-1-positive patients after 1 year of antiretroviral therapy. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):405-15.</citation>
    <PMID>16652047</PMID>
  </reference>
  <reference>
    <citation>Almeida M, Cordero M, Almeida J, Orfao A. Abnormal cytokine production by circulating monocytes and dendritic cells of myeloid origin in ART-treated HIV-1+ patients relates to CD4+ T-cell recovery and HCV co-infection. Curr HIV Res. 2007 May;5(3):325-36.</citation>
    <PMID>17504174</PMID>
  </reference>
  <reference>
    <citation>Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman MM, Lehmann PV, Valdez H. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol. 2004 Apr 15;172(8):4907-16.</citation>
    <PMID>15067070</PMID>
  </reference>
  <reference>
    <citation>Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P, Patterson S. Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10. J Infect Dis. 2009 Jun 15;199(12):1862-71. doi: 10.1086/599122.</citation>
    <PMID>19419334</PMID>
  </reference>
  <reference>
    <citation>Chang JJ, Lacas A, Lindsay RJ, Doyle EH, Axten KL, Pereyra F, Rosenberg ES, Walker BD, Allen TM, Altfeld M. Differential regulation of toll-like receptor pathways in acute and chronic HIV-1 infection. AIDS. 2012 Mar 13;26(5):533-41. doi: 10.1097/QAD.0b013e32834f3167.</citation>
    <PMID>22210629</PMID>
  </reference>
  <reference>
    <citation>Fan Z, Huang XL, Kalinski P, Young S, Rinaldo CR Jr. Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection. Clin Vaccine Immunol. 2007 Sep;14(9):1127-37. Epub 2007 Jul 18.</citation>
    <PMID>17634507</PMID>
  </reference>
  <reference>
    <citation>Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci U S A. 2004 May 18;101(20):7669-74. Epub 2004 May 5.</citation>
    <PMID>15128934</PMID>
  </reference>
  <reference>
    <citation>Hodges A, Sharrocks K, Edelmann M, Baban D, Moris A, Schwartz O, Drakesmith H, Davies K, Kessler B, McMichael A, Simmons A. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol. 2007 Jun;8(6):569-77. Epub 2007 May 13.</citation>
    <PMID>17496896</PMID>
  </reference>
  <reference>
    <citation>Lester RT, Yao XD, Ball TB, McKinnon LR, Kaul R, Wachihi C, Jaoko W, Plummer FA, Rosenthal KL. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS. 2008 Mar 30;22(6):685-94. doi: 10.1097/QAD.0b013e3282f4de35.</citation>
    <PMID>18356597</PMID>
  </reference>
  <reference>
    <citation>Majumder B, Janket ML, Schafer EA, Schaubert K, Huang XL, Kan-Mitchell J, Rinaldo CR Jr, Ayyavoo V. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape. J Virol. 2005 Jul;79(13):7990-8003.</citation>
    <PMID>15956545</PMID>
  </reference>
  <reference>
    <citation>Sabado RL, O'Brien M, Subedi A, Qin L, Hu N, Taylor E, Dibben O, Stacey A, Fellay J, Shianna KV, Siegal F, Shodell M, Shah K, Larsson M, Lifson J, Nadas A, Marmor M, Hutt R, Margolis D, Garmon D, Markowitz M, Valentine F, Borrow P, Bhardwaj N. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood. 2010 Nov 11;116(19):3839-52. doi: 10.1182/blood-2010-03-273763. Epub 2010 Aug 6.</citation>
    <PMID>20693428</PMID>
  </reference>
  <reference>
    <citation>Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, Dionisio R, Charles D, Campbell-Gardener L, Olson WC, Sanders RW, Moore JP. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog. 2007 Nov;3(11):e169.</citation>
    <PMID>17983270</PMID>
  </reference>
  <reference>
    <citation>Smed-Sörensen A, Loré K, Walther-Jallow L, Andersson J, Spetz AL. HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood. 2004 Nov 1;104(9):2810-7. Epub 2004 Jul 1.</citation>
    <PMID>15231570</PMID>
  </reference>
  <reference>
    <citation>Tan DB, Yong YK, Lim A, Tan HY, Kamarulzaman A, French M, Price P. Robust interferon-α and IL-12 responses by dendritic cells are related to efficient CD4+ T-cell recovery in HIV patients on ART. Clin Immunol. 2011 May;139(2):115-21. doi: 10.1016/j.clim.2011.02.015. Epub 2011 Feb 23.</citation>
    <PMID>21429806</PMID>
  </reference>
  <reference>
    <citation>Yonkers NL, Rodriguez B, Asaad R, Lederman MM, Anthony DD. Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells. PLoS One. 2011;6(9):e23884. doi: 10.1371/journal.pone.0023884. Epub 2011 Sep 1.</citation>
    <PMID>21912648</PMID>
  </reference>
  <reference>
    <citation>Frleta D, Ochoa CE, Kramer HB, Khan SA, Stacey AR, Borrow P, Kessler BM, Haynes BF, Bhardwaj N. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest. 2012 Dec;122(12):4685-97. doi: 10.1172/JCI64439. Epub 2012 Nov 19.</citation>
    <PMID>23160198</PMID>
  </reference>
  <reference>
    <citation>Dillon SM, Robertson KB, Pan SC, Mawhinney S, Meditz AL, Folkvord JM, Connick E, McCarter MD, Wilson CC. Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2008 May 1;48(1):1-12. doi: 10.1097/QAI.0b013e3181664b60.</citation>
    <PMID>18300699</PMID>
  </reference>
  <reference>
    <citation>Butera ST, Roberts BD, Folks TM. Regulation of HIV-1 expression by cytokine networks in a CD4+ model of chronic infection. J Immunol. 1993 Jan 15;150(2):625-34.</citation>
    <PMID>8380428</PMID>
  </reference>
  <reference>
    <citation>Hoshino S, Konishi M, Mori M, Shimura M, Nishitani C, Kuroki Y, Koyanagi Y, Kano S, Itabe H, Ishizaka Y. HIV-1 Vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency. J Leukoc Biol. 2010 Jun;87(6):1133-43. doi: 10.1189/jlb.0809547. Epub 2010 Feb 9.</citation>
    <PMID>20145198</PMID>
  </reference>
  <reference>
    <citation>McNamara LA, Ganesh JA, Collins KL. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. J Virol. 2012 Sep;86(17):9337-50. doi: 10.1128/JVI.00895-12. Epub 2012 Jun 20.</citation>
    <PMID>22718820</PMID>
  </reference>
  <reference>
    <citation>Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987 Apr 16-22;326(6114):711-3. Erratum in: Nature 1990 Mar 8;344(6262):178.</citation>
    <PMID>3031512</PMID>
  </reference>
  <reference>
    <citation>Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci AS. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A. 1990 Jan;87(2):782-5.</citation>
    <PMID>2300561</PMID>
  </reference>
  <reference>
    <citation>Saleh S, Wightman F, Ramanayake S, Alexander M, Kumar N, Khoury G, Pereira C, Purcell D, Cameron PU, Lewin SR. Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology. 2011 Oct 12;8:80. doi: 10.1186/1742-4690-8-80.</citation>
    <PMID>21992606</PMID>
  </reference>
  <reference>
    <citation>Tiemessen CT, Kilroe B, Martin DJ. Interleukin-8 fails to induce human immunodeficiency virus-1 expression in chronically infected promonocytic U1 cells but differentially modulates induction by proinflammatory cytokines. Immunology. 2000 Sep;101(1):140-6.</citation>
    <PMID>11012765</PMID>
  </reference>
  <reference>
    <citation>Winckelmann, A., et al. Toll-like Receptor 9 Agonist Treatment Decreases the Proviral Reservoir in Peripheral Blood and Could Impact HIV-specific Immunity in Patients on cART. Conference on Retroviruses and Opportunistic Infections (CROI) (2013).</citation>
  </reference>
  <reference>
    <citation>Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood. 2007 Dec 15;110(13):4161-4. Epub 2007 Sep 19.</citation>
    <PMID>17881634</PMID>
  </reference>
  <reference>
    <citation>Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljeström P, Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005 Feb 24;433(7028):887-92. Epub 2005 Feb 13.</citation>
    <PMID>15711573</PMID>
  </reference>
  <reference>
    <citation>Wille-Reece U, Flynn BJ, Loré K, Koup RA, Miles AP, Saul A, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med. 2006 May 15;203(5):1249-58. Epub 2006 Apr 24.</citation>
    <PMID>16636134</PMID>
  </reference>
  <reference>
    <citation>Zhang Z, Kim T, Bao M, Facchinetti V, Jung SY, Ghaffari AA, Qin J, Cheng G, Liu YJ. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity. 2011 Jun 24;34(6):866-78. doi: 10.1016/j.immuni.2011.03.027.</citation>
    <PMID>21703541</PMID>
  </reference>
  <reference>
    <citation>Zhang Z, Yuan B, Lu N, Facchinetti V, Liu YJ. DHX9 pairs with IPS-1 to sense double-stranded RNA in myeloid dendritic cells. J Immunol. 2011 Nov 1;187(9):4501-8. doi: 10.4049/jimmunol.1101307. Epub 2011 Sep 28.</citation>
    <PMID>21957149</PMID>
  </reference>
  <reference>
    <citation>Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, Okamoto-Tanaka M, Ishizaki H, Miyoshi J, Matsumoto M, Seya T. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):252-7. Epub 2006 Dec 26.</citation>
    <PMID>17190817</PMID>
  </reference>
  <reference>
    <citation>Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, Marie I, Levy DE, Bhardwaj N. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res. 2011 Aug 15;71(16):5467-76. doi: 10.1158/0008-5472.CAN-10-3988. Epub 2011 Jul 5.</citation>
    <PMID>21730023</PMID>
  </reference>
  <reference>
    <citation>Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009 Jul 6;206(7):1589-602. doi: 10.1084/jem.20090247. Epub 2009 Jun 29.</citation>
    <PMID>19564349</PMID>
  </reference>
  <reference>
    <citation>Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann L, Müller M, Sacher A, Racz P, Steinman RM, Uguccioni M, Ignatius R. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 2009 Apr;5(4):e1000373. doi: 10.1371/journal.ppat.1000373. Epub 2009 Apr 10.</citation>
    <PMID>19360120</PMID>
  </reference>
  <reference>
    <citation>Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates. Vaccine. 2010 Oct 21;28(45):7256-66. doi: 10.1016/j.vaccine.2010.08.098. Epub 2010 Sep 21.</citation>
    <PMID>20846528</PMID>
  </reference>
  <reference>
    <citation>Vagenas P, Aravantinou M, Williams VG, Jasny E, Piatak M Jr, Lifson JD, Salazar AM, Blanchard JL, Gettie A, Robbiani M. A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One. 2010 Sep 21;5(9):e12891. doi: 10.1371/journal.pone.0012891.</citation>
    <PMID>20877632</PMID>
  </reference>
  <reference>
    <citation>Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, Schendel DJ. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med. 2007 Apr 12;5:18.</citation>
    <PMID>17430585</PMID>
  </reference>
  <reference>
    <citation>Checkley Luttge, M., et al. Natural Killer Cells Can Target and Eliminate Latently HIV-1-Infected Primary T cells following Proviral Reactivation. Conference on Retroviruses and Opportunistic Infections (CROI) (2013).</citation>
  </reference>
  <reference>
    <citation>Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, Breton G, Trumpfheller C, Pollak S, Shimeliovich I, Duque-Alarcon A, Pan L, Nelkenbaum A, Salazar AM, Schlesinger SJ, Steinman RM, Sékaly RP. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011 Nov 21;208(12):2357-66. doi: 10.1084/jem.20111171. Epub 2011 Nov 7.</citation>
    <PMID>22065672</PMID>
  </reference>
  <reference>
    <citation>Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011 Jan 20;29(3):330-6. doi: 10.1200/JCO.2010.30.7744. Epub 2010 Dec 13.</citation>
    <PMID>21149657</PMID>
  </reference>
  <reference>
    <citation>Poly-ICLC Investigational Brochure (Hiltonol®, Oncovir).</citation>
  </reference>
  <reference>
    <citation>Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, Schlesinger SJ, Steinman RM. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med. 2012 Feb;271(2):183-92. doi: 10.1111/j.1365-2796.2011.02496.x. Epub 2012 Jan 4. Review.</citation>
    <PMID>22126373</PMID>
  </reference>
  <reference>
    <citation>Marcus PI, Sekellick MJ. Combined sequential treatment with interferon and dsRNA abrogates virus resistance to interferon action. J Interferon Cytokine Res. 2001 Jun;21(6):423-9.</citation>
    <PMID>11440640</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <results_first_submitted>December 21, 2017</results_first_submitted>
  <results_first_submitted_qc>February 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2018</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Nina Bhardwaj</investigator_full_name>
    <investigator_title>Professor, Medicine - Director, Immunotherapy Program</investigator_title>
  </responsible_party>
  <keyword>Human immunodeficiency virus 1</keyword>
  <keyword>Combined Antiretroviral Therapy</keyword>
  <keyword>Poly-ICLC</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly ICLC</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Poly-ICLC</title>
          <description>Poly-ICLC: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Normal Saline</title>
          <description>Normal Saline: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Poly-ICLC</title>
          <description>Poly-ICLC: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Normal Saline</title>
          <description>Normal Saline: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="9.32"/>
                    <measurement group_id="B2" value="34.33" spread="4.03"/>
                    <measurement group_id="B3" value="39.73" spread="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Participants With Adverse Events</title>
        <description>Safety measured by number of participants with adverse events.</description>
        <time_frame>Up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Poly-ICLC</title>
            <description>Poly-ICLC: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Normal Saline</title>
            <description>Normal Saline: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Participants With Adverse Events</title>
          <description>Safety measured by number of participants with adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Interferon-gamma-inducible Protein-10 (IP-10) Level</title>
        <description>One of the biomarkers of cellular immune activation and exhaustion quantified by flow cytometry. Normal range is 7.8–500 pg/ml.</description>
        <time_frame>Day 2 and Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Poly-ICLC</title>
            <description>Poly-ICLC: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Normal Saline</title>
            <description>Normal Saline: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Interferon-gamma-inducible Protein-10 (IP-10) Level</title>
          <description>One of the biomarkers of cellular immune activation and exhaustion quantified by flow cytometry. Normal range is 7.8–500 pg/ml.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381.43" spread="187.67"/>
                    <measurement group_id="O2" value="100.65" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="450.51" spread="144.9"/>
                    <measurement group_id="O2" value="139.39" spread="42.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD8 CD38 (Mean of Fluorescence)</title>
        <description>the CD38-activation marker on CD8 T-cells (CD8/CD38).</description>
        <time_frame>Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Poly-ICLC</title>
            <description>Poly-ICLC: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Normal Saline</title>
            <description>Normal Saline: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml.</description>
          </group>
        </group_list>
        <measure>
          <title>CD8 CD38 (Mean of Fluorescence)</title>
          <description>the CD38-activation marker on CD8 T-cells (CD8/CD38).</description>
          <units>mean fluorescent intensity (MFI)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.69" spread="6.77"/>
                    <measurement group_id="O2" value="2.35" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NK Cell Number</title>
        <description>Natural killer cells or NK cells are part of the innate immune defense against infection and cancer.</description>
        <time_frame>at 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Poly-ICLC</title>
            <description>Poly-ICLC: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Normal Saline</title>
            <description>Normal Saline: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml.</description>
          </group>
        </group_list>
        <measure>
          <title>NK Cell Number</title>
          <description>Natural killer cells or NK cells are part of the innate immune defense against infection and cancer.</description>
          <units>cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.68" spread="16.06"/>
                    <measurement group_id="O2" value="19.41" spread="15.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in CD4+ Tcell-associated HIV-1 RNA as Compared to Baseline</title>
        <description>CD4+ Tcell-associated HIV-1 RNA to determine whether Poly-ICLC disrupts viral latency in HIV-1-infected individuals on anti-retroviral therapy.Viral transcription assessed by monitoring cell associated HIV-1 RNA. Percent change compared to baseline.</description>
        <time_frame>Baseline, Day 2, Day 4, Day 8, Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Poly-ICLC</title>
            <description>Poly-ICLC: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Normal Saline</title>
            <description>Normal Saline: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in CD4+ Tcell-associated HIV-1 RNA as Compared to Baseline</title>
          <description>CD4+ Tcell-associated HIV-1 RNA to determine whether Poly-ICLC disrupts viral latency in HIV-1-infected individuals on anti-retroviral therapy.Viral transcription assessed by monitoring cell associated HIV-1 RNA. Percent change compared to baseline.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.8" spread="30.65"/>
                    <measurement group_id="O2" value="186.3" spread="163.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.8" spread="90.3"/>
                    <measurement group_id="O2" value="254.7" spread="223.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.0" spread="112.3"/>
                    <measurement group_id="O2" value="66.33" spread="22.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.6" spread="247.2"/>
                    <measurement group_id="O2" value="126.7" spread="65.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Poly-ICLC</title>
          <description>Poly-ICLC: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Normal Saline</title>
          <description>Normal Saline: Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgias</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>erythema</sub_title>
                <description>Injection site reaction</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Injection site reaction</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low neutrophils count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, gender homogeneity, and exclusion of older individuals (&gt;55 years) and common comorbidities such as cardiovascular disease and diabetes limit the generalizability of the safety findings in the HIV-infected population as a whole.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Nina Bhardwaj</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-824-8427</phone>
      <email>nina.bhardwaj@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

